Literature DB >> 12413857

Membrane-permeant derivatives of mannose-1-phosphate.

Synke Rutschow1, Joachim Thiem, Christian Kranz, Thorsten Marquardt.   

Abstract

For treatment of congenital disorder of glycosylation type Ia (CDG-Ia) membrane-permeant derivatives of mannose-1-phosphate are required. Employing biologically cleavable phosphate protecting groups advantageous precursor derivatives could be synthesized following a facile approach. Their enzymatic cleavages using esterase from porcine liver (E.C. 3.1.1.1) were investigated.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12413857     DOI： 10.1016/s0968-0896(02)00269-9

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN： 0968-0896            Impact factor:   3.641


  9 in total

1.  Improvement of dolichol-linked oligosaccharide biosynthesis by the squalene synthase inhibitor zaragozic acid.

Authors:  Micha A Haeuptle; Michael Welti; Heinz Troxler; Andreas J Hülsmeier; Timo Imbach; Thierry Hennet
Journal:  J Biol Chem       Date:  2010-12-23       Impact factor: 5.157

2.  Enzymatic and cellular study of a serotonin N-acetyltransferase phosphopantetheine-based prodrug.

Authors:  Yousang Hwang; Surajit Ganguly; Anthony K Ho; David C Klein; Philip A Cole
Journal:  Bioorg Med Chem       Date:  2006-12-13       Impact factor: 3.641

3.  Chemical Therapies for Congenital Disorders of Glycosylation.

Authors:  Paulina Sosicka; Bobby G Ng; Hudson H Freeze
Journal:  ACS Chem Biol       Date:  2021-11-17       Impact factor: 4.634

Review 4.  Therapies and therapeutic approaches in Congenital Disorders of Glycosylation.

Authors:  Christian Thiel; Christian Körner
Journal:  Glycoconj J       Date:  2012-09-16       Impact factor: 2.916

Review 5.  The congenital disorders of glycosylation: a multifaceted group of syndromes.

Authors:  Erik A Eklund; Hudson H Freeze
Journal:  NeuroRx       Date:  2006-04

6.  A phosphorylated prodrug for the inhibition of Pin1.

Authors:  Song Zhao; Felicia A Etzkorn
Journal:  Bioorg Med Chem Lett       Date:  2007-09-26       Impact factor: 2.823

Review 7.  Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients.

Authors:  Hudson H Freeze
Journal:  Biochim Biophys Acta       Date:  2009-09

Review 8.  CDG Therapies: From Bench to Bedside.

Authors:  Sandra Brasil; Carlota Pascoal; Rita Francisco; Dorinda Marques-da-Silva; Giuseppina Andreotti; Paula A Videira; Eva Morava; Jaak Jaeken; Vanessa Dos Reis Ferreira
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

9.  Biochemical phenotype of a common disease-causing mutation and a possible therapeutic approach for the phosphomannomutase 2-associated disorder of glycosylation.

Authors:  Giuseppina Andreotti; Emilia Pedone; Assunta Giordano; Maria Vittoria Cubellis
Journal:  Mol Genet Genomic Med       Date:  2013-03-27       Impact factor: 2.183
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.